AstraZeneca has discreetly halted the production of their COVID-19 vaccine, which has also been officially withdrawn from the EU market.
This significant development occurred shortly after their admission in court that the vaccine could cause severe blood clotting issues.
The pharmaceutical giant is currently facing a class action lawsuit, where affected individuals and their families are seeking compensation for the vaccine’s side effects.
As of May 7th, AstraZeneca's COVID-19 vaccine will no longer be available in European markets.
"The impact of this decision is profound," AstraZeneca commented. "We will now collaborate with regulators and our partners to determine a clear path forward to close this chapter and wrap up our substantial role in addressing the COVID-19 pandemic."
The company noted a decline in demand for their vaccine, stating it is "no longer manufactured or supplied."
According to an official document on the EU website, the European Commission confirms that the marketing authorization for the AstraZeneca vaccine has been retracted.
"Per the holder’s request, the marketing authorization issued by Decision C(2021) 698(final) on January 29, 2021, for the medicinal product 'Vaxzevria - COVID-19 Vaccine (ChAdOx1-S[recombinant])' is withdrawn."
This news marks a pivotal moment.
After several years on the market, the vaccine is being withdrawn, raising questions about potential undisclosed side effects and the timing of this decision amidst a major lawsuit.
Coverage of this major development by mainstream media has been minimal, prompting a call for widespread sharing of this news.
You must be logged in to post a comment.